Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The pharmacogenomics market is projected to reach USD 5.8 billion by 2028 from an estimated USD 3.5 billion in 2023, at a CAGR of 10.6% during the forecast period. The growth of this market can be attributed to the research and development efforts aimed at drug discovery and development, and growing focus on personalized medicines.
“The kits & reagents segment accounted for the largest share by product & service in 2022.”
In 2022, the kits & reagents segment accounted for the largest share of product type in the global pharmacogenomics market. The factors such as growing demand for high quality reagents for genomics studies, increasing focus on development of personalized medicines, and growing number of research projects in the field of genomics are driving the growth of this market.
““The Asia Pacific region is growing in the pharmacogenomics market during the forecast period of 2023-2028.”
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including growing adoption of advanced sequencing technologies and booming healthcare sector are propelling the growth of pharmacogenomics market in the region.
Increased funding and investments from pharmaceutical and biotechnology companies aimed at advancing the healthcare sector are expected to propel the growth of the pharmacogenomics market in the Asia Pacific region. According to R&D Magazine, Asia has become the world's foremost region in research and development (R&D) investment, claiming over 44% of the global R&D share. The region is steadily gaining an additional half-percent share each year, and if this trend persists, it could represent more than half of all R&D investments by 2030. China is actively enhancing its R&D infrastructure and human resources capabilities, maintaining a consistent commitment to spending, ambition, and long-term planning. These factors are expected to contribute for the highest CAGR of the regionbetween 2023 to 2028.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
By Region: North America -30%, Europe -20%, Asia-Pacific -30%, Latin America -15% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
Illumina, Inc. (US)
Thermo Fisher Scientific Inc. (US)
Danaher Corporation (US)
Laboratory Corporation of America Holdings (US)
Charles River Laboratories (US)
Eurofins Scientific (Luxembourg)
Bio-Rad Laboratories, Inc. (US)
Agilent Technologies, Inc. (US)
BD (US)
QIAGEN (Netherlands)
F. Hoffmann-La Roche Ltd. (Switzerland)
Revvity (US), IQVIA Inc. (US)
Mesa Labs, Inc. (US)
Medpace (US)
MGI Tech Co., Ltd. (China)
Takara Bio Inc. (Japan)
PacBio (US)
New England Biolabs (US)
BGI (China), Novogene Co., Ltd. (China)
SOPHiA GENETICS (Switzerland), Fios Genomics (UK)
Personalis, Inc. (US)
BioAI Health Inc. (US)
NeoGenomics Laboratories (US)
Macrogen, Inc. (South Korea).)
Research Coverage:
This research report categorizes the pharmacogenomics market by product & service (kits & reagents ( sequencing kits and reagents, PCR kits and reagents, microarray kits and reagents, and other kits & reagents) and service), technology (sequencing, PCR, microarray, and other technologies), disease area (cancer, cardiovascular, neurological diseases, and other disease areas), application (personalized medicine, clinical research, and drug discovery & preclinical development), and end user (academic & research institutes, pharmaeutical & biotechechnology companies, and contract research organization)
The report provides in-depth information on significant factors influencing the growth of the pharmacogenomics market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, mergers, and acquisitions within the pharmacogenomics market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmacogenomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (growing incidence and prevalence of chronic and genetic diseases and rising investments and funding to support genomic projects), restraints (challenges in data integration and interpretation, and issues related to drug response variability), opportunities (growing usage of genomics in specialized/personalized medicine), and challenges (ethical & regulatory issues, concern related to patient privacy & data accessibility) influencing the growth of the market.
Product & Service Development/Innovation: Detailed insights on newly launched products/services of the pharmacogenomics market
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the pharmacogenomics market
Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), among others in the market.